# Xilio Therapeutics (XLO) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/XLO
## Company Profile
- Ticker: XLO
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy, Oncology
## Stock Data
- Close: 9.18 USD
- Market cap: 53916139.8 USD
- Last updated: 2026-08-11
## Business Overview
### Tumor-Activated Immunotherapy
Xilio Therapeutics engineers cytokines, antibodies, and T-cell engagers that remain masked until activated within the tumor microenvironment.
### XTX501
XTX501 combines PD-1 blockade with a masked IL-2 mechanism and is intended as a potential combination backbone across solid tumors.
### Masked T-Cell Engagers
Earlier programs include XTX601 targeting CLDN18.2 and a multispecific engager targeting PSMA and STEAP1.
## Why The Stock Is Moving

As of Aug 11, 2026, XLO was little changed and closed at $9.18. No new same-company headline was identified in the current news window.

## Future Catalysts

- An IND submission for XTX501 is planned around mid-2026.
- A Phase 1 study of XTX501 is expected to begin in the second half of 2026.
- Initial Phase 1 data in metastatic non-small cell lung cancer are expected in the second half of 2027.

## Recent News
- 2026-07-06 20:30 EST — [Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/XLO/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--f70a7f47) — Source: Xilio Therapeutics
- 2026-06-29 11:30 EST — [Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer](https://biopharmsignal.com/news/XLO/xilio-therapeutics-appoints-ben-harshbarger-as-chief-legal-officer-d248a423) — Source: Xilio Therapeutics
- 2026-05-12 11:30 EST — [Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates](https://biopharmsignal.com/news/XLO/xilio-therapeutics-reports-first-quarter-2026-financial-results-and-provides-pip-859a3b0c) — Source: Xilio Therapeutics
- 2026-04-17 20:01 EST — [Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2](https://biopharmsignal.com/news/XLO/xilio-therapeutics-announces-new-preclinical-data-at-aacr-annual-meeting-for-xtx-61e9b86b) — Source: Xilio Therapeutics
- 2026-04-16 11:30 EST — [Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors](https://biopharmsignal.com/news/XLO/xilio-therapeutics-appoints-cheryl-r-blanchard-ph-d-to-its-board-of-directors-4b7702b0) — Source: Xilio Therapeutics